🔗 Share this article

While the US continues making historic adjustments to its immunization guidelines, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by casting doubt on coronavirus vaccines throughout the global health crisis and has concentrated on alleged deaths following COVID-19 immunization in her brief tenure at the FDA.

Proposed Changes to Childhood Immunization Schedule

Health officials were set to reveal sweeping changes to the childhood vaccine schedule recently, aligning the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US out of step with much of the international standard with little proof for public health gain. This reveal has been delayed until the new year.

In place of Vinay Prasad, Høeg is listed to speak at the meeting. She was just designated temporary leader of the FDA’s CDER, the fifth appointee to head the division this year.

A Shift at the Regulatory Body

This interim role could signify a closer partnership between the pharmaceutical and biologics branches as Høeg and Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon dismantling already-approved immunizations at the FDA.

Høeg has often pushed for halting specific childhood shot schedules in the US in order to be more like the Danish model, a country with universal health coverage and a population roughly the size of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on immunizations – typically the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Doubts Over Qualifications

The appointee has no apparent track record in medication creation, approval processes or management, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the FDA chief and CBER since spring.

“It seems she lacks to have any of the qualifications” for running the drug-regulation department, stated Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in running a major agency. She is not an expert in pharmaceutical oversight.”

Former heads of CBER would “understand regulatory frameworks and the science of pharmaceutical innovation”, said Janet Woodcock. “Frankly, she doesn’t have the kind of background that previous people who ran the center have had.”

This division has an immense workload at the FDA, the former commissioner pointed out.

“The public just zeroes in on the novel medication approvals, but the generic program approves numerous off-brand pharmaceuticals. There is also a biologic copycat branch, non-prescription drug unit and so forth, and each of these have to be looked after,” she explained. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a substantial administrative component to the role, which manages in excess of 5,000 staff members. “It’s a huge leadership role, if you execute it properly,” Woodcock added.

Agency Reaction and Contentious Policies

Regarding inquiries about Dr. Høeg's credentials and whether this appointment signifies increased cooperation among agency officials on immunizations, a representative said that the “questions stem from incorrect premises”.

“This background is consistent with the functions of her role,” the official stated, citing the period Høeg spent counseling the agency head on “drug safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg inherits the commissioner’s recently launched fast-track approval initiative, a controversial rapid therapy clearance system that allegedly concerned her preceding directors. “How are these medications being selected for this voucher program? Who takes the decisions?” Dr. Howard questioned. “There is a lot of confidentiality going on at the agency right now.”

Overall, he said, “the FDA looks to be trending towards laxer rules of all drugs, with the exception of immunizations.”

Established Track Record on Immunizations

With vaccines, Høeg has a more established, if concerning, track record, some experts observe. She released a analysis using unverified crowd-sourced reports to assess the rate of heart inflammation following Covid vaccination. She consulted for the Florida chief medical officer Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “wish list” for the incoming federal leadership encompassed changing regulations for novel immunizations and ending “unnecessary” immunizations, she said post-election on a audio program. At the agency, Høeg has reportedly floated the idea of preventing young men from obtaining Covid vaccines.

“She’s an thorough dogmatist who commences with her preconceived notions and works backwards to fit the evidence in a extremely disingenuous, fraudulent way,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with other contrarians, {like|